Ratings Moves: AIR,...
Health Care: Drugs
Sunesis Pharmaceuticals Inc (SNSS: NASDAQ)
$5.46 0.05 | 0.92%
05/17/13 - 04:00 PM ET
Company Income Statement
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Sales | 3.75M | 5.00M | 33.08K | 3.76M |
| Cost of Sales | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Operating Profit | 3.75M | 5.00M | 33.08K | 3.76M |
| Selling, General, and Administrative Expenses | 9.18M | 8.30M | 7.00M | 7.75M |
| Research & Development | 29.18M | 22.56M | 14.43M | 13.25M |
| Operating Income before D & A (EBITDA) | -34.61M | -25.87M | -21.41M | -17.23M |
| Depreciation & Amortization | 431.00K | 112.00K | 150.23K | 341.58K |
| Interest Income | 0.00 | 0.00 | 0.00 | 21.63K |
| Other Income - Net | -7.49M | 6.02M | -3.18M | -21.10M |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -42.53M | -19.95M | -24.74M | -40.57M |
| Interest Expense | 1.86M | 300.00K | 0.00 | 1.19K |
| Pre-Tax Income | -44.38M | -20.25M | -24.74M | -40.57M |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -43.95M | -20.14M | -24.59M | 0.00 |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -43.95M | -20.14M | -24.59M | 0.00 |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -43.95M | -20.14M | -24.59M | -40.23M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-43.95M | -20.14M | -24.59M | 1.92M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -43.95M | -20.14M | -24.59M | -27.56M |
| Basic EPS from Continuing Ops. | -0.91 | -0.43 | -0.99 | -11.82 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -0.91 | -0.43 | -0.99 | -11.82 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -0.91 | -0.43 | -0.99 | -11.82 |
| Basic Normalized Net Income/Share | -0.91 | -0.43 | -0.99 | n.a. |
| EPS fr Continuing Ops. | -0.91 | -0.43 | -0.99 | -11.82 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -0.91 | -0.43 | -0.99 | -11.82 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -0.91 | -0.43 | -0.99 | -11.82 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-0.91 | -0.43 | -0.99 | n.a. |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with SNSS
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- UserGopher Gold
- ContributorStocks Under-$10 Setting Up...
Latest SNSS Headlines from TheStreet
- Sunesis To Present At Upcoming Investor Conferences 05.10.13 | 03:05 pm
- Sunesis Pharmaceuticals Reports First Quarter Financial Results And Recent Highlights 05.09.13 | 07:05 am
- Sunesis To Host Conference Call On May 9th To Discuss First Quarter Financial Results And Recent Highlights 05.02.13 | 07:05 am
- Sunesis To Present At The Needham & Company 12th Annual Healthcare Conference 04.24.13 | 07:04 am
- Sunesis Pharmaceuticals Reports Fourth Quarter And Full-Year 2012 Financial Results And Recent Highlights 03.13.13 | 07:03 am
- Sunesis To Present At The 25th Annual Roth Conference 03.11.13 | 07:03 am
- Sunesis To Host Conference Call On March 13th To Discuss Fourth Quarter And Full-Year 2012 Financial Results And Recent Highlights 03.06.13 | 07:03 am
- Sunesis To Present At Upcoming Investor Conferences 02.20.13 | 07:02 am
- Sunesis To Present At The Leerink Swann 2013 Global Healthcare Conference 02.06.13 | 07:02 am
- 8 Stocks Under $10 Soaring Higher 01.31.13 | 03:01 pm
Press Releases for SNSS
- Over $400 Million Raised By U.S. Life Sciences Companies Through At-the-Market (ATM) Offerings In 2012, Reports Brinson Patrick - PR Newswire 04.08.13 | 08:04 am
Partner Headlines for SNSS
- Sunesis Pharmaceuticals Earnings: Here’s Why the Stock is Up Now - Wall St. Cheat Sheet 05.09.13 | 11:05 am
- Upcoming AML Treatments - Which Company Will Fly? - Seeking Alpha 12.03.12 | 09:12 am
- Morning Market Movers - Benzinga 09.11.12 | 09:09 am
- Arena's Lorcaserin PASSES FDA Approval and 2 Stocks that Have Hit 52-Week Highs - Wall St. Cheat Sheet 06.28.12 | 10:06 am
- Biotechnology Stocks To Watch Ahead Of ASCO 2012: Part 3 - Seeking Alpha 05.25.12 | 08:05 pm
- Benzinga's Microcap Movers for Friday March 30, 2012 - Benzinga 04.01.12 | 09:04 am
- Sunesis and Royalty Pharma Announce $25M Vosaroxin Royalty Agreement - Benzinga 03.29.12 | 04:03 pm
- 16 Stocks Under $5 Being Bought Up By Insiders And The Smart Money - Seeking Alpha 09.16.11 | 05:09 pm
- 6 Speculative Biotech Stocks Smart Money Loves - Seeking Alpha 05.23.11 | 09:05 am
- Cyclin-Dependent Cancer Confab Preview - SeekingAlpha.com 04.17.10 | 04:04 pm
